Trevi Therapeutics Prepares for Third Quarter Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI), a pioneering biopharmaceutical company, is gearing up to unveil its third-quarter financial results. The announcement is set to take place on a Thursday, with a conference call scheduled for 4:30 p.m. ET. This event will provide investors and interested parties with crucial insights regarding the company’s progress.
Key Event Details
During this conference call, Trevi’s senior management will share an in-depth corporate update as well as a financial review covering the quarter that ended on September 30, 2025. Those wishing to participate in the live call can dial in using the provided numbers, facilitating both domestic and international access. There will be no access codes required to join the call.
Innovative Solutions for Chronic Cough
Trevi Therapeutics is cultivating a specialized therapeutical approach with Haduvio™, an investigational therapy formulated as oral nalbuphine extended-release. This treatment is being developed specifically for patients suffering from chronic cough linked to idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC).
The significance of Haduvio lies in its ability to uniquely target the mechanisms behind chronic cough, offering new hope for those who have not found relief with existing treatments. Initial trials have indicated that Haduvio could significantly reduce cough frequency, marking it as a potential game-changer in managing chronic cough conditions.
Understanding the Impact of Chronic Cough
Chronic cough is a troublesome symptom that affects many individuals, particularly those with IPF and non-IPF ILD. Research indicates that approximately 150,000 patients in the U.S. are living with IPF, and a significant portion of them experience uncontrollable cough episodes. Meanwhile, nearly 228,000 patients with non-IPF ILD are also affected.
The implications of chronic cough are profound, as patients may experience an overwhelming number of coughing fits daily, which can number up to 1,500. This persistent cough not only affects individuals' physical well-being but can also lead to psychological distress and reduced quality of life.
Challenges and Opportunities for Trevi Therapeutics
Another crucial area of focus for Trevi is the treatment of refractory chronic cough, which persists for more than eight weeks, despite addressing underlying issues. The estimated number of individuals suffering from RCC ranges between 2 to 3 million in the U.S., creating a substantial opportunity for novel treatment options.
Trevi Therapeutics is dedicated to proposing the trade name Haduvio for nalbuphine ER, emphasizing its potential in this challenging therapeutic space. Regulatory evaluation is still pending, and Trevi is preparing for the extensive assessments required to bring Haduvio to market.
Company Commitment to Innovation
Trevi's commitment to developing effective therapies for unmet medical needs reflects its mission to improve patient outcomes. As the company prepares for its financial update, stakeholders will be eager to hear about the advancements made in their clinical trials and the broader implications for patients suffering from chronic cough related conditions.
For those seeking further information about Trevi Therapeutics, the company maintains an informative online presence that covers their ongoing research and development efforts. Interested parties are encouraged to visit their official website.
Frequently Asked Questions
What is Trevi Therapeutics focusing on in its upcoming report?
Trevi Therapeutics is focusing on providing insights into its financial results for the third quarter of 2025 and an update on its Haduvio therapy.
What is Haduvio and its purpose?
Haduvio is an investigational therapy aimed at treating chronic cough associated with various lung diseases, including idiopathic pulmonary fibrosis.
When will the financial results be announced?
The financial results and conference call are scheduled for November 13, 2025, at 4:30 p.m. ET.
How can investors participate in the conference call?
Investors can dial in using provided phone numbers to join the conference call without needing an access code.
What unmet needs is Trevi addressing with its therapies?
Trevi aims to address the significant unmet medical needs in chronic cough management, especially in patients experiencing refractory chronic cough.
